Home » Stocks » CBIO

Catalyst Biosciences, Inc. (CBIO)

Stock Price: $4.27 USD 0.04 (0.95%)
Updated Jun 24, 2021 2:35 PM EDT - Market open
Market Cap 132.80M
Revenue (ttm) 6.05M
Net Income (ttm) -74.63M
Shares Out 28.39M
EPS (ttm) -3.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 24
Last Price $4.27
Previous Close $4.23
Change ($) 0.04
Change (%) 0.95%
Day's Open 4.24
Day's Range 4.15 - 4.28
Day's Volume 165,499
52-Week Range 4.05 - 7.55

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Catalyst Biosciences (CBIO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of -2.60% and 46.70%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2021 and...

1 month ago - GlobeNewsWire

CB 2782-PEG patent protection extended until at least 2038 CB 2782-PEG patent protection extended until at least 2038

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will present a corporate overview ...

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and full-year ending ...

3 months ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: PAA, KDMN, RESN
4 months ago - 24/7 Wall Street

SOUTH SAN FRANCISCO, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced that in connection with its previously announced public offering o...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today presented positive pre-clinical data from its Marzeptacog alfa (activated) – MarzAA, progra...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) (the “Company”) today announced the closing of an underwritten public offering of 8,700,000 shares...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO (the “Company”) today announced the pricing of an underwritten public offering of 8,700,000 shares ...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it is offering shares of its common stock in an underwritten public offering...

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two e-poster presentations at the European Association for Haemophilia and Allie...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the members of its management team will participate in a fireside chat hoste...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) presented a poster today at the 62nd Annual American Society of Hematology (ASH) meeting, held vi...

6 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it will host a research and development call on the Company's systemic compl...

6 months ago - GlobeNewsWire

Increased analyst coverage over the last few weeks might led to solid price appreciation for stocks like ODP (ODP), Myers (MYE), Catalyst Biosciences (CBIO), Vicor (VICR) and Bally's (BALY).

Other stocks mentioned: MYE, ODP, VICR
6 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conferenc...

6 months ago - GlobeNewsWire

Catalyst Biosciences is targeting the hemophilia space with a strong candidate treating types A and B with inhibitors, and second targeting type B. Current standard of care NovoSeven is administered int...

7 months ago - Seeking Alpha

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Catalyst Biosciences (CBIO), UFP Industries (UFPI), VeriSign (VRSN), InMode (INMD) and Castle Bi...

Other stocks mentioned: CSTL, INMD, UFPI, VRSN
7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced a trials in progress poster presentation on Marzeptacog alfa (activated) – or Mar...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the third quarter ended September 30, 202...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer, and Clinton Musi...

7 months ago - GlobeNewsWire

CB 2782-PEG patent protection extended until at least 2038 CB 2782-PEG patent protection extended until at least 2038

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., senior vice president of translational research, wil...

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Nassim Usman, Ph.D., president and chief executive officer and Clinton Mu...

9 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2020 ...

10 months ago - GlobeNewsWire

Subcutaneous marzeptacog alfa (activated) (MarzAA) rapidly achieves and maintains therapeutic levels

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today reported that the Compensation Committee of Catalyst’s Board of Directors granted a non-q...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced that it has been added to the Russell 2000® Index effective at the U.S. market ...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced two presentations at the upcoming International Society on Thrombosis and Haem...

11 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), today announced the closing of an underwritten public offering of 4,615,384 shares of its commo...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Mr. Charles Democko as Senior Vice President, Regulatory Af...

1 year ago - GlobeNewsWire

CB 2679d-GT demonstrates robust expression of FIX in multiple preclinical models CB 2679d-GT demonstrates robust expression of FIX in multiple preclinical models

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO) today announced that it is offering shares of its common stock in an underwritten public offerin...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced the appointment of Clinton Musil as its new chief financial officer, effective...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced final efficacy and safety data from its Phase 2b trial of DalcA, a next-genera...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced that Nassim Usman, Ph.D., president and chief executive officer of Catalyst Bi...

1 year ago - GlobeNewsWire

Results support subcutaneous dosing regimen of the Phase 3 Registrational trial Results support subcutaneous dosing regimen of the Phase 3 Registrational trial

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., June 08, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced oral and poster presentations at the upcoming World Foundation of Hemophilia V...

1 year ago - GlobeNewsWire

MarzAA Phase 3 study first patient enrollment targeted before year end following FDA and EMA regulatory feedback

1 year ago - GlobeNewsWire

FIX patent including DalcA and CB 2679d-GT, now issued in all major markets FIX patent including DalcA and CB 2679d-GT, now issued in all major markets

1 year ago - GlobeNewsWire

Top Ranked Momentum Stocks to Buy for April 21st

Other stocks mentioned: CNR, GSV, TRWH
1 year ago - Zacks Investment Research

Final results to be presented during the second quarter Final results to be presented during the second quarter

1 year ago - GlobeNewsWire

Catalyst Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and other...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the Eur...

1 year ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage biopharmaceutical company developing novel treatments for hemophilia and othe...

1 year ago - GlobeNewsWire

About CBIO

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treat... [Read more...]

Industry
Biotechnology
Founded
2002
CEO
Nassim Usman
Employees
56
Stock Exchange
NASDAQ
Ticker Symbol
CBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CBIO stock is "Buy." The 12-month stock price forecast is 18.00, which is an increase of 321.55% from the latest price.

Price Target
$18.00
(321.55% upside)
Analyst Consensus: Buy